Income statement
CAD
Annual
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | 914K | 3M |
| Gross Profit | 414K | 1M |
| Operating Income | -1M | -3M |
| EBITDA | -5M | -6M |
| Net Income | -5M | -7M |
| EPS (Diluted) | — | — |
Healthcare
Live Price
Offline$0.006
+0.00% today
1Y Change
+0.00%
Window
Jun 20, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 20, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Relevium Technologies Inc. (RLLVF) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and up 0.0% across the available one-year price window (Jun 20, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -69.3%, EPS growth of +30.2%, a dividend yield of 0.0%. What stands out right now is revenue -69.3%, EPS +30.2%, free cash flow +94.1% with operating margin -161.5% and ROIC 88.9%. Valuation is more restrained than many high-expectation growth names at price/sales 2.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RLLVF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RLLVF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RLLVF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RLLVF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.0M
+225.5% YoY
FY Net Income
-$6.9M
-29.1% YoY
Free Cash Flow
-$2.2M
-1598.9% YoY
Revenue Growth
-69.3%
EPS Growth
+30.2%
Gross Margin
45.4%
Net Margin
-587.6%
Income statement
CAD
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | 914K | 3M |
| Gross Profit | 414K | 1M |
| Operating Income | -1M | -3M |
| EBITDA | -5M | -6M |
| Net Income | -5M | -7M |
| EPS (Diluted) | — | — |
Balance sheet
CAD
| Metric | 2021 | 2020 |
|---|---|---|
| Cash & Equivalents | 64K | 195K |
| Total Assets | 759K | 4M |
| Total Liabilities | 6M | 4M |
| Shareholder Equity | -5M | 56K |
| Total Debt | 3M | 3M |
| Net Debt | 3M | 3M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
-1595.6% YoY
Capital Expenditures
4K
Free Cash Flow
2M
-1598.9% YoY
Key ratios
Gross Margin
45.4%
Operating Margin
-161.5%
Net Margin
-587.6%
ROE
221.4%
Debt / Equity
-0.65x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.